Authors : Ankem Kovidha; Atluri Varsha; Vattikutti Uma Maheshwara Rao

Volume/Issue : Volume 11 - 2026, Issue 10 - October

Google Scholar : https://tinyurl.com/yc5mpufd

DOI : https://doi.org/10.38124/ijisrt/26Oct187

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Cutaneous adverse drug reactions (CADRs) are among the most frequently encountered medication-related complications in hospitalized patients, particularly those receiving polypharmacy regimens. Non-steroidal antiinflammatory drugs (NSAIDs) are well-documented triggers of hypersensitivity-mediated dermatological reactions.  Case Summary: We report the case of a 35-year-old female patient with right knee osteoarthritis and a four-year history of Type 2 Diabetes Mellitus who developed diffuse erythematous skin lesions over the thighs and abdomen following initiation of Zerodol SP (Aceclofenac + Paracetamol + Serratiopeptidase) and Tenlin M Forte (Teneligliptin + Metformin). Clinical evaluation, causality assessment, and temporal correlation identified the NSAID combination as the probable causative agent.  Outcome: Prompt withdrawal of Zerodol SP, substitution with paracetamol monotherapy, and supportive care led to complete resolution of the cutaneous reaction. The patient was discharged in stable condition on Day 6.  Conclusion: This case underscores the importance of systematic ADR monitoring, early clinical pharmacist intervention, and individualized therapeutic decision-making in patients with comorbidities.

Keywords : Cutaneous Adverse Drug Reaction; NSAID Hypersensitivity; Aceclofenac; Erythema; Drug Safety; Pharmacovigilance; Osteoarthritis; Type 2 Diabetes Mellitus.

References :

1. Revuz J, Valeyrie-Allanore L. Drug reactions. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 3rd ed. London: Elsevier Saunders; 2012. p. 335–356.
2. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87(3):177–182.
3. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274(1):29–34.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
5. Baumann TJ. Pain management. In: DiPiro JT, editor. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York: McGraw-Hill; 2017.
6. Bircher AJ. Approach to the patient with drug hypersensitivity. Immunol Allergy Clin North Am. 2009;29(3):405–418.
7. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2017.
8. Stockley IH. Stockley's Drug Interactions. 11th ed. London: Pharmaceutical Press; 2016.
9. Harrison TR. Harrison's Principles of Internal Medicine. 20th ed. New York: McGraw-Hill; 2018.